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INTRODUCTION 
 
Prolactin is a well-characterized hormone required for 
terminal differentiation of mammary epithelial cells and 
for synthesis of milk components during lactation [1–3]. 
Beyond its recognized role in the development and 
differentiation of the normal breast, prolactin causally 
contributes to the pathogenesis of breast cancer via an 
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Progesterone receptor (PR) isoforms can drive unique phenotypes in luminal breast cancer (BC). Here, we 
hypothesized that PR-B and PR-A isoforms differentially modify the cross-talk between prolactin and fatty 
acid synthase (FASN) in BC. We profiled the responsiveness of the FASN gene promoter to prolactin in 
T47Dco BC cells constitutively expressing PR-A and PR-B, in the PR-null variant T47D-Y cell line, and in PR-null 
T47D-Y cells engineered to stably re-express PR-A (T47D-YA) or PR-B (T47D-YB). The capacity of prolactin to 
up-regulate FASN gene promoter activity in T47Dco cells was lost in T47D-Y and TD47-YA cells. Constitutively 
up-regulated FASN gene expression in T47-YB cells and its further stimulation by prolactin were both 
suppressed by the prolactin receptor antagonist hPRL-G129R. The ability of the FASN inhibitor C75 to 
decrease prolactin secretion was more conspicuous in T47-YB cells. In T47D-Y cells, which secreted notably 
less prolactin and downregulated prolactin receptor expression relative to T47Dco cells, FASN blockade 
resulted in an augmented secretion of prolactin and up-regulation of prolactin receptor expression. Our 
data reveal unforeseen PR-B isoform-specific regulatory actions in the cross-talk between prolactin and 
FASN signaling in BC. These findings might provide new PR-B/FASN-centered predictive and therapeutic 
modalities in luminal intrinsic BC subtypes.  
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autocrine/paracrine loop involving prolactin binding to its 
membrane-associated prolactin receptor (PRLR). Similar 
to what has been reported for estrogen and progesterone, 
studies in vitro implicate a role for prolactin in breast 
cancer cell proliferation and survival [4–11], and high 
levels of this hormone have been shown to drive 
mammary tumor development in mice [12, 13]. In 
women, elevated levels of prolactin correlate with 
increased breast cancer risk and metastasis, whereas lower 
levels of prolactin/PRLR in clinical samples associate 
with improved patient survival [14–19]. Early studies with 
the PRLR antagonist hPRL-G129R – a variant of normal 
human prolactin with a single amino acid substitution 
mutation – revealed its capacity to inhibit the prolactin-
induced oncogenic signaling responsible for cancer cell 
proliferation [20–24]. More recently, prolonged treatment 
with hPRL-G129R in ovarian cancer models was found to 
antagonize the signaling activities of the prolactin/PRLR 
tumoral axis and to inhibit tumor growth by inducing 
destructive autophagy [25].  
 
Despite the biological and clinical relevance of the 
prolactin/PRLR axis, incomplete knowledge of the 
underlying network has largely precluded its therapeutic 
exploitation in specific breast cancer subtypes. Upon 
engagement of prolactin with PRLR, the resulting 
activation of JAK/STAT, PI3K, and MAPK signaling 
pathways enhances the survival, proliferation, 
differentiation, and motility of normal breast epithelial 
cells [7]. Activation of these transduction cascades enables 
not only the expansion of the breast epithelial cell 
population during pregnancy, but also the differentiation of 
those epithelial cells responsible for the synthesis and 
secretion of milk during lactation [7, 26, 27]. This 
association might similarly lead to augmented growth and 
motility of breast cancer cells. Although less clearly 
defined, a loss of responsiveness of breast cancer tissues to 
the pro-differentiation activities of prolactin might be 
linked to its pathogenic role in certain breast cancer 
subtypes and/or disease stages. In this regard, it is well 
known that prolactin-driven differentiation is characterized 
by its capacity to orchestrate the expression of key lipid 
biosynthesis genes and regulate the activity of lipogenic 
enzymes, leading to cytoplasmic lipid droplets in lactating 
mammary epithelial cells [28]. A key lipogenic enzyme for 
the development, functional competence, and maintenance 
of the lactating mammary gland is fatty acid synthase 
(FASN), which participates in the prolactin-promoted 
generation of large quantities of medium- and long-chain 
fatty acids and total fatty acid contents in milk [29–32]. 
FASN is a well-characterized driver of metabolic 
reprogramming in cancer cells [33–35]. Interestingly, the 
metabolo-oncogenic nature of FASN in breast cancer does 
not rely on its lactogenic activity, but rather on its ability to 
provide energy, macromolecules for membrane synthesis, 
and lipid signals, that facilitate cancer cell survival and 
proliferation, and also regulate the activity of other 
oncogenic pathways [33–37]. However, little is known 
about how prolactin and FASN signaling interact during 
breast cancer progression. The finding that suppression of 
FASN-driven endogenous lipogenesis is sufficient to 
restore normal ductal-like structures in the mammary 
gland irrespective of the mutational background of 
undifferentiated malignant phenotypes [37], underpins the 
notion that FASN gene expression must be closely 
controlled and regulated for the differentiation and 
maintenance of normal-like tissue architectures in the 
breast [38, 39].  
 
The phenotypic effects of prolactin on normal mammary 
epithelium involve spatio-temporal crosstalk between 
PRLR and progesterone/progesterone receptor (PR) 
signaling. Progesterone induces the expression of the 
PRLR, PR and PRLR cooperate during ductal branch 
growth in the mammary gland, and PR signaling represses 
the PRLR-triggered lactogenic signaling that induces milk 
protein expression [40–42]. Progesterone signaling in 
breast tissues is mediated by two co-expressed PR 
isoforms – full-length PR-B and N-terminal truncated PR-
A – which regulate the same, as well as distinct, gene sets 
[43–45]. For instance, whereas PR-A is both necessary and 
sufficient to elicit the progesterone-dependent reproductive 
responses for uterine development and fertility, PR-B is 
required for the normal proliferative and differentiative 
responses of the mammary gland to progesterone [46–49]. 
An ever-growing body of complex and sometimes 
conflicting evidence has shown that isoform-specific PR 
expression is a context-dependent driver of distinct luminal 
breast cancer phenotypes in terms of the endocrine 
sensitivity, proliferative capacity, and cancer stem-like cell 
behavior [50–62]. However, how the close functioning of 
the progesterone/PR and prolactin/PRLR signaling axes 
that drive the lactogenic/lipogenic phenotypic outcomes in 
normal mammary gland [63] might be altered in breast 
cancer tissues remains largely unexplored. Here, we tested 
the hypothesis that the PR-B and PR-A isoforms 
differentially modify the ability of prolactin to 
transcriptionally regulate the expression of the FASN gene 
in PR+ breast cancer cells. We also tested the contrary 
hypothesis that prolactin secretion and/or PRLR 
expression are affected by pharmacological interruption of 




Expression of FASN and PRLR mRNAs is 
significantly elevated in PR-positive breast cancer  
 
FASN is an endogenous PR-responsive gene [64–67], 
which might explain, at least in part, the simultaneous 
increase in expression of FASN and PR proteins early 
during human mammary carcinogenesis [68]. We 
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interrogated transcriptional data from the METABRIC 
[69, 70] to explore the association between FASN and PR 
in breast cancer (Figure 1). FASN mRNA expression was 
significantly higher in PR-positive breast tumors than in 
PR-negative tumors (p < 0.0001; n=1,700), as 
determined by PR gene expression profiles. PRLR 
expression was also significantly elevated in PR-




Figure 1. Differential enrichment of FASN, prolactin, and PRLR genes in breast cancer subtypes. FASN, prolactin, and PRLR mRNA 
expression levels in primary breast tumors from the METABRIC project classified into distinct subtypes using different classifiers. (PR+, n=903 
versus PR-, n=797, Mann Whitney test; 3-genes signature, estrogen receptor (ER)-/HER2-, n=290, ER+/HER2- high proliferation, n=603, 
ER+/HER2+ low proliferation, n=619, HER2+, n=188, ANOVA with Dunn’s multiple comparison test; PAM50: basal, n=161, claudin-low, n=186, 
HER2 enriched, n=190, luminal A, n=631, luminal B, n= 412, ANOVA with Dunn’s multiple comparison test). 
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expression was not significantly different between the two 
subgroups (p = 0.5755). It was therefore of interest to 
evaluate whether FASN mRNA expression correlated with 
that of PRLR. PRLR was among the top-100 genes 
positively correlated with FASN gene expression (r = 0.31, 
p < 0.0001) in the METABRIC breast cancer dataset. 
Indeed, when the data set was classified according to the 
five intrinsic subtypes (luminal-A, luminal-B, HER2-
enriched, claudin-low, and basal-like) using the research-
based 50-gene prediction analysis of microarray (PAM50) 
classifier [71], both FASN and PRLR (but not prolactin) 
mRNAs were found to be significantly higher in HER2-
enriched and luminal subtypes than in highly 
aggressive/poor prognosis basal-like and claudin-low 
subtypes (Figure 1). The highest levels of FASN and 
PRLR mRNAs were detected in HER2-enriched and 
luminal-A subtypes, respectively.  
 
Maximum prolactin secretion and PRLR expression 
requires both PR-A and PR-B isoforms 
 
To evaluate the relevance of PR isoform expression and 
ratio on the regulatory activity of prolactin for FASN gene 
expression, we used the PR-A/PR-B-positive (T47Dco) and 
PR-null (T47D-Y) variants of the estrogen receptor 
(ER)/PR-positive breast cancer cell line T47D. T47Dco 
cells endogenously express equimolar levels of PR-A and 
PR-B in a constitutive and estrogen-independent manner, 
thereby allowing the study of the functional relevance of 
PR without the confounding effects of estrogen [44, 62, 
72–75]. T47D-Y cells can also be used to determine the 
effect of PR isoform variants or mutants by stably 
reintroducing PR-A or PR-B on expression vectors. The 
resulting cell lines, termed T47D-YA (stably expressing 
the full-length PR-A isoform) and T47D-YB (stably 
expressing the full-length PR-B isoform), have been 
widely employed to evaluate the independent signaling 
function of each PR isoform [43, 62, 72–75]. Here, we 
employed all four T47D cell lines, each with a different PR 
content (Figure 2A), to test for isoform-specific prolactin 
gene regulation and functional interactions with the FASN 
gene.   
 
ELISA-based quantification of prolactin content in the 
conditioned medium of T47Dco, T47D-Y, T47D-YA, 
and T47D-YB cultures revealed considerably lower 
amounts (~85%) in PR-null T47D-Y cultures than in 
T47Dco cultures (Figure 2B). Although the individual 
re-expression of each PR isoform was not sufficient to 
reach the levels of prolactin found in T47Dco cultures, 
the stable re-expression of PR-A and PR-B notably 
augmented by 3.7- and 4.8-fold, respectively, the extra-
cellular amounts of prolactin in T47D-Y cultures. We 
also compared the four cell types in terms of PRLR 
abundance by immunoblotting equivalent cell extracts 
using an antibody against PRL4 (Figure 2A). Analysis 
showed that T47Dco cells likewise harbored an abundant 
amount of PRLR, whereas a notably decreased amount 
of PRLR was detected in PR-null T47D-Y cells. T47D-
YB cells expressed PRLR at slightly higher levels than 
T47D-YA cells. These findings, altogether, reveal not 
only a close correlation between the status of prolactin 
secretion and PRLR expression, but also that both PR-A 
and PR-B are required to achieve maximum levels of 
prolactin secretion and PRLR expression.  
 
Progesterone receptor isoforms differentially impact 
baseline FASN expression 
 
To assess how the PR status might alter baseline FASN 
promoter activity, T47Dco, T47DY, T47D-YA, and 
T47D-YB cells were transfected with a luciferase 
reporter vector encoding a sterol regulatory element-
containing FASN promoter sequence fused with firefly 
luciferase. As shown in Figure 2C, the absence of both 
PR isoforms failed to alter luciferase expression in 
T47D-Y cells with respect to baseline levels in T47Dco 
cells. Intriguingly, FASN promoter activity was reduced 
by approximately 50% in cells exclusively expressing 
the PR-A isoform (T47D-YA), but increased by more 
than 90% in cells exclusively expressing the PR-B 
isoform (T47D-YB). At the protein level, immuno-
blotting confirmed the lower amounts of FASN in 
T47D-YA cells and the slightly higher FASN levels in 
T47D-YB cells (Figure 2A).  
 
Prolactin-induced up-regulation of FASN gene 
expression is PR-B isoform-specific  
 
Transient transfection experiments with the FASN 
reporter demonstrated the ability of graded concentrations 
of prolactin (50, 100, and 200 ng/mL) to dose-
dependently up-regulate (up to 2.1-fold at 200 ng/mL 
prolactin) promoter activity in T47Dco cells (Figure 2D, 
top). PR-null T47D-Y cells, however, remained mostly 
insensitive to the regulatory effects of prolactin on the 
FASN reporter. We examined PR isoform-dependent, 
prolactin-driven FASN promoter activity, finding that 
T47D cells containing PR-A (T47D-YA cells) were 
completely unresponsive to prolactin. By contrast, the sole 
presence of PR-B preserved the ability of prolactin to 
increase FASN promoter activity, as previously observed 
in T47Dco cells (Figure 2D, top). Indeed, the presence of 
PR-B in the absence of PR-A significantly boosted the 
response of the FASN promoter to prolactin 
concentrations as low as 50 ng/mL, suggesting that 
prolactin-induced activation of the FASN reporter is 
largely mediated through PR-B. We further found that 
prolactin-induced FASN promoter activity was blocked in 
cells transiently transfected with a truncated version of the 
proximal FASN gene promoter in which the region 
responsible for SREBP binding was deleted 
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(FASNΔSRE; Figure 2D, bottom), overall suggesting that 
prolactin activates the FASN promoter primarily through 
the SREBP1 regulatory site [76–78].  
 
The PRLR-specific antagonist hPRL-G129R impedes 
prolactin-driven activation of FASN gene expression 
 
To substantiate that prolactin activates FASN gene 
expression by its engagement with PRLR, we used the 
PRLR-specific antagonist hPRL-G129R [20–25,  
 
79–82]. Prolactin-induced activation of FASN gene 
expression (at 200 ng/mL) in T47Dco and T47D-YB 
cells was completely inhibited by co-incubation with 
hPRL-G129R at a relatively low concentration of 
1000 ng/mL (i.e., 5-fold-excess of prolactin) (Figure 
3, top). Further, PRLP-specific blockade with hPRL-
G129R sufficed to return the overactive FASN 
promoter in T47D-YB cells to the baseline state seen 
in T47Dco cells. Immunoblotting assays failed to 




Figure 2. Exogenous prolactin activates the FASN gene promoter in a PR-B/SBREP-dependent manner. (A). Immunoblotting of 
baseline expression status of PR-A, PR-B, PRLR, and FASN proteins in T47Dco, T47D-Y, T47D-YA and T47D-YB breast cancer cell lines. β-actin was 
used to control for protein loading and transfer. (B). Immunoassay-based quantification of baseline autocrine prolactin secretion into the 
extracellular milieu of T47Dco, T47D-Y, T47D-YA and T47D-YB breast cancer cell lines. (C, D). Estradiol-depleted cells were transiently transfected 
with a plasmid containing a luciferase gene driven by a 178-bp FASN gene promoter fragment harboring a SREBP-binding site, flanked by auxiliary 
NF-Y and Sp-1 sites or with a similar construct in which the SREBP domain was deleted. The next day, cells were treated with graded concentrations 
of recombinant prolactin (PRL) in 0.5% CCS. After 24 h, cells were lysed and luciferase activity was measured. Luciferase activity was expressed as 
relative (fold) change in transcriptional activities of FASN promoter-transfected cells in response to prolactin treatment after normalization to pRL-
CMV activity. Each experimental value represents the mean fold increase (columns) ± S.D. (bars) from at least three separate experiments in which 
triplicate wells were measured. Luciferase activity in prolactin-treated cells was compared with that in vehicle-treated control cells (* P < 0.05; ** P 
< 0.005).  
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Figure 3. Exogenous prolactin activates FASN gene promoter activity by engaging PRLR. Top. Estradiol-depleted cells were 
transiently transfected with a plasmid containing a luciferase gene driven by a 178-bp FASN gene promoter fragment harboring a SREBP-
binding site, flanked by auxiliary NF-Y and Sp-1 sites as described in Figure 2C, 2D. The next day, cells were treated with 200 ng/mL prolactin 
(PRL) in the absence or presence of a 5-fold-excess of the prolactin antagonist hPRL-G129R (1000 ng/mL) in 0.5% CCS. After ~24 h of 
incubation, cells were lysed, luciferase activity was measured and relative (fold) changes in transcriptional activities of FASN promoter-
luciferase-transfected cells were calculated. The data are shown as the means (columns) ± S.D. (bars) from three separate experiments 
(performed in duplicate). Luciferase activity in prolactin- and/or hPRL-G129R-treated cells was compared with that in vehicle-treated control 
cells (* P < 0.05; ** P < 0.005). Bottom. Estradiol-depleted cells were treated with 200 ng/mL PRL in the absence or presence of a 5-fold 
excess of hPRL-G129R in 0.5% CCS for 48 h. Immunoreactive bands for PR-A, PR-B, and PRLR proteins were analyzed by immunoblotting as 
described in Figure 2A. β-actin was used to control for protein loading and transfer. Figure shows a representative immunoblot analysis. 
Similar results were obtained in 3 independent experiments. 
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in response to prolactin, hPRL-G129R, or their 
combination (Figure 3, bottom); however, hPRL-
G129R co-treatment prevented the ability of prolactin 
to marginally down-regulate PR-A and PR-B 
expression in T47D-YA and T47D-YB cells, 
respectively. These findings, altogether, imply that the 
prolactin-FASN signaling axis acts through PRLR in 
T47D cells, and suggest the specific functional 
engagement of the PR-B isoform as the driver of 
FASN gene responsiveness to the regulatory effects of 
prolactin/PRLR.  
 
FASN inhibition suppresses PR-A and PR-B 
expression 
 
We previously demonstrated that FASN blockade 
suppresses the well-documented capacity of estradiol 
to up-regulate PR expression in endometrial cancer 
cells [83, 84]. We therefore explored the possibility 
that FASN signaling regulates the constitutive 
expression of both PR isoforms irrespective of 
estradiol stimulation. As shown in Supplementary 
Figure 1, the expression of PR-A and PR-B in T47Dco 
cells was dose-dependently suppressed in the 
presence of graded concentrations of the FASN 
inhibitor C75. Indeed, PR-A and PR-B expression 
was very low to undetectable in the presence of 10 
μg/mL C75 not only in T47Dco cells but also in 
T47D-YA and T47D-YB cells (Supplementary Figure 
1).  
 
FASN inhibition modifies prolactin secretion and 
PRLR expression in a PR isoform-dependent 
manner 
 
We next tested the hypothesis that FASN signaling 
regulates prolactin secretion in a PR isoform-
dependent manner (Figure 4A). Prolactin secretion in 
T47Dco cells was reduced by C75 in a dose-dependent 
manner (up to approximately 80% suppression at 10 
μg/mL C75; Figure 4A, top). In T47D-YA cells, 
however, prolactin secretion was significantly reduced 
by only 50% at the same concentration of C75. 
Conversely, C75 concentrations as low as 2.5 μg/mL 
sufficed to decrease prolactin secretion by 50% in 
T47-YB cells, whereas the suppression of secretion as 
high as 80% was observed at 10 μg/mL C75 (Figure 
4A, top). A significant, dose-dependent up-regulation 
of prolactin secretion occurred in PR-null T47D-Y 
cells exposed to graded concentrations of C75 (up to 
approximately 170%). We then explored the ability of 
FASN signaling to regulate PRLR expression. 
Remarkably, we observed the complete loss of PRLR 
expression in T47Dco, TD47Y-A, and T47D-YB cells 
grown in the presence of C75 (Figure 4A, bottom). By 
contrast, PRLR protein expression in PR-null Y47D-Y 
cells was conspicuously up-regulated in response to 
C75 (Figure 4A, bottom).  
 
FASN inhibition suppresses epithelial-to-
mesenchymal transition-related aggressiveness in 
PR-null T47DY cells  
 
Both PR and PRLR have been suggested to act as as 
promoters of more differentiated phenotypes via 
suppression of the epithelial-to-mesenchymal (EMT) 
program. Indeed, loss of PR in T47D-Y cells has been 
associated with a change in cell morphology to a more 
mesenchymal-like phenotype, accompanied by 
increased cell motility, and up-regulation of EMT-
associated genes [85, 86]. Similarly, prolactin blockade 
in epithelial-like breast cancer cells has been shown to 
induce mesenchymal-like phenotypic changes and 
enhance invasiveness, whereas activation of PRLR in 
mesenchymal-like breast cancer cells suppresses 
mesenchymal properties and reduces invasive behaviors 
[87, 88]. A robust surrogate marker of aggressive breast 
cancer phenotype via regulation of EMT is interleukin-6 
(IL-6) [89–92]. We therefore investigated whether the 
apparent ability of FASN blockade to restore a prolactin 
autocrine function in T47D-Y cells via augmented 
secretion of PR and re-activation of PRLR expression 
might impact the EMT-related status of IL-6 expression. 
EMT-like PR-null T47D-Y cells released extremely 
high levels of IL-6 into the extracellular milieu when 
compared with PR-A/-B-expressing T47Dco parental 
cells (approx. 13-fold increase; Figure 4B). The FASN 
inhibitor C75 not only suppressed the baseline IL-6 
expression in T47Dco parental cells, but further reduced 
(by more 50%) the augmentation of IL-6 secretion 
promoted by loss of PR in T47D-Y cells (Figure 4B).  
 
PRLR inhibition decreases FASN expression in 
HER2-overexpressing breast cancer cells 
 
Several studies suggest that there is potential cooperation 
between PRLR and HER2 during breast cancer 
progression [82, 93, 94]. We speculated that, if a cross-talk 
between HER2 and autocrine prolactin/PRLR signaling is 
actively involved in the well-known FASN over-
expressing-phenotype of HER2-positive breast cancer cells 
[36, 95–98], blockade of PRLR should then reduce the 
ability of HER2 to constitutively up-regulate FASN gene 
expression. We found that whereas exogenous stimulation 
with prolactin dose-dependently increased FASN promoter 
activity in HER2-negative MCF-7/neo control cells, it 
failed to promote any further increase in activity of the 
already hyperactive FASN gene promoter in MCF-
7/HER2 cells (Figure 5). hPRL-G129R fully prevented the 
positive regulatory effects of prolactin on the FASN gene 
in MCF-7/neo parental cells and partially reduced the 
overactive FASN gene promoter in MCF- 
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Figure 4. Pharmacological blockade of FASN activity modifies autocrine prolactin secretion in a PR-dependent manner. (A). Top. 
Autocrine prolactin secretion levels in the extracellular milieu of estradiol-depleted cells cultured in the absence or presence of graded 
concentrations of C75 in 0.5% CCS for 48 h were determined by a commercially available EASIA kit. Data are means (columns) ± S.D. (bars) from 
three independent experiments performed in duplicate. Secreted amounts of prolactin in C75-treated cells were compared with those in vehicle-
treated control cells (* P < 0.05; ** P < 0.005). Bottom. Cell lysates strictly obtained from the same experimental replicates employed in A were 
subjected to immunoblotting for PRLR protein expression. β-actin was used to control for protein loading and transfer. Figure shows a 
representative immunoblot analysis. Similar results were obtained in 3 independent experiments. (B). Autocrine IL-6 levels in the extracellular 
milieu of estradiol-depleted cells cultured in the absence or presence of 10 μg/mL C75 in 0.5% CCS for 48 h were determined by a commercially 




Figure 5. HER2 overexpression prevents prolactin-induced activation of the FASN gene promoter. Estradiol-depleted MCF-7/neo and 
MCF-7/Her2-18 cells were transiently transfected with a plasmid containing a luciferase gene driven by a 178-bp FASN gene promoter fragment 
harboring a SREBP-binding site, flanked by auxiliary NF-Y and Sp-1 sites or with a similar construct in which the SREBP domain was deleted. The next 
day, cells were treated with recombinant prolactin (PRL) in the presence or absence of hPRL-G129R in 0.5% CCS. After ~24 h of incubation, cells 
were lysed, luciferase activity was measured and relative (fold) changes in transcriptional activities of FASN promoter-luciferase-transfected cells 
were calculated. The data are shown as the means (columns) ± S.D. (bars) from three separate experiments (performed in duplicate). Luciferase 
activity in PRL- and/or G129R-treated cells was compared with that in vehicle-treated control cells (* P < 0.05; ** P < 0.005). 
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7/HER2 cells, thus suggesting that PRLR signaling 
actively engages HER2 signaling to fully hyperactivate the 




Prolactin has a central role in mammary gland 
development and terminal differentiation of mammary 
epithelial cells. The prolactin/PRLR-signaling axis has 
been consistently shown to play a permissive role in the 
development of primary breast carcinomas and distant 
metastatic lesions [3, 5, 7, 12, 13, 18, 20, 22, 99, 100]. 
Recent studies have, however, questioned the role of 
prolactin in breast cancer development/progression and 
have highlighted a putative suppressor role in breast 
tumorigenesis [87, 101]. This latter role is supported by 
the association between prolactin/PRLR down-
regulation and significantly better survival outcome in 
patients with breast cancer [88, 102–105], which is 
consistent with the lack of anti-tumorigenic effects and 
therapeutic benefits observed in clinical trials with 
PRLR antagonists [106]. Accordingly, the restoration/ 
activation of prolactin/PRLR signaling has been shown 
to promote cell differentiation and reverse highly 
proliferative, invasive, mesenchymal and tumorigenic 
phenotypes, such as those of the ER/PR double-negative 
MDA-MB-231 breast cancer model [107]. How might 
we reconcile these apparently conflicting pro- and anti-
tumorigenic roles of prolactin?  
 
We took advantage of the T47Dco luminal breast cancer 
cell line, which constitutively express high levels of ER 
and PR, and allows the study of the unliganded, 
progesterone-independent regulatory effects of human 
PRs in ER-positive luminal-like breast cancer without 
the confounding requirement of estradiol to stimulate 
PR expression. In addition to this, we employed the PR-
negative T47D subline T47D-Y, in which cloning 
approaches restored either PR-A or PR-B expression, 
and used these cells to study the regulatory roles of each 
isoform in isolation [72, 108]. Because all of these 
models share the natural background of PR+ luminal 
breast cancer, in which we detected a positive 
correlation between PRLR and FASN genes in the 
METABRIC repository, they are expected to contain 
the appropriate ancillary coregulatory factors needed for 
faithful regulation of prolactin/PR-dependent genes. 
Our results lead us to propose that the PR isoform-
specific regulation of distinct regulatory responses in 
the cross-talk between prolactin and FASN might be 
involved in the diverse phenotypic outcomes arising 
from the prolactin/PRLR signaling axis in luminal 
breast cancer.  
 
We first assessed how PR-B and PR-A isoforms could 
modify the ability of prolactin to regulate the 
expression of the FASN gene in PR+ breast cancer 
cells. Historically, PR-B has been characterized as a 
strong “positive” regulator of the effects of 
progesterone, whereas PR-A is often regarded as a 
ligand-independent mediator of gene repression. Also, 
the isoforms differ with regard to the positive versus 
negative regulatory direction and also the type of 
regulated genes. Thus, whereas PR-B mostly regulates 
the expression of genes required for cell proliferation 
[43], PR-A mainly controls the expression of genes 
involved in cell adherence, cell morphology, and 
resistance to apoptosis [50, 109, 110]. We found that 
the ability of the prolactin/PRLR signaling to 
transcriptionally up-regulate FASN gene expression 
was specifically dictated by: a.) the obligatory 
presence of PR-B to enable prolactin-driven FASN 
gene activation, and b.) the necessary lack of PR-A to 
facilitate maximum FASN gene activation in response 
to prolactin. Accordingly, whereas PR-B+ T47-YB 
cells were exquisitely responsive to exogenous 
prolactin in terms of FASN gene up-regulation, both 
PR-null T47D-Y and PR-A+ T47D-YA cells remained 
completely unresponsive to the FASN regulatory 
effects of prolactin. When both PR isoforms are co-
expressed (i.e., T47Dco), prolactin-induced FASN 
activation is considerably dampened relative to that of 
cells exclusively expressing PR-B (i.e., T47D-YB). 
PR-A trans-repression of PR-B might explain this 
observation and likely implicates a negative effect of 
PR-A within PR heterodimers, as has been reported in 
multiple models [110–115]. In this case, however, how 
do PR isoform-specific signaling events impact the 
ability of the same “classical” prolactin/PRLR/JAK2/ 
STAT5 pathway to differentially mediate prolactin-
induced FASN gene transcription? Of note, the ability 
of PR-B to facilitate prolactin-driven FASN activation 
required an SREBP-binding site in the FASN gene 
promoter. Therefore, PR isoform-specific actions 
might not simply be explained in terms of STAT5-
driven transcriptional regulation of the FASN gene 
promoter, but instead suggest that the distinct ability 
of each PR isoform to cooperate with STAT5 would 
differentially impact SREBP-1c expression. The 
prolactin/PRLR/JAK2/STAT5 signaling pathway 
drives fat synthesis and proliferation via augmented 
expression of SREBP-1c [116, 117]. STAT5 modulates 
the expression and nuclear distribution of SREBP1, 
thereby regulating its biological functions including the 
regulation of lipogenic genes such as FASN. In fact, 
downregulation of (phospho-active) STAT5 decreases, 
whereas its overexpression increases, the activation of 
the SREBP1 promoter [118]. Intriguingly, the ability of 
PR to drive JAK/STAT-dependent transcriptional 
responses requires the so-called CD domain of PR-B, 
which is located in the N-terminal B-upstream segment 
(BUS) region of full-length PR-B – and absent in  
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PR-A – and is essential for proliferative signaling in 
breast cancer cells [119, 120]. The CD domain of PR-B 
is required for PR-B-dependent expression of STAT5 
which, in turn, then complexes with PR-B on a specific 
subset of PR-target genes. Indeed, STAT5 appears to 
operate as a pioneer transcription factor that “opens” 
sites in chromatin for subsequent PR-B-driven 
transcriptional activation of target genes [120]. It is 
therefore tempting to speculate that the BUS region of 
PR-B might function as the shared signaling hub of the 
prolactin/PRLR-driven STAT5 and PR-B (but not PR-
A) signaling axes. By placing the lipogenic master 
regulator SREBP-1c as one of the select target genes 
coregulated by STAT5 and PR-B, we can explain the 
PR-B isoform-specific regulatory actions on the cross-
talk between prolactin and FASN signaling in luminal 
breast cancer cells (Figure 6). In a scenario in which 
constitutive activation of PRLR and HER2 (e.g., MCF-
7/HER2 cells) leads to a dissociation between 
prolactin/PRLR and inducible STAT5 activation, which 
becomes constitutive via hyperactivation not only of 
JAK2 but also of PI3K/AKT/mTOR and MAPK 
transducers, maximal transcriptional activation of the 
FASN gene is no longer responsive to exogenous 
stimulus with prolactin, but can be partially prevented 
by PRLR antagonists such as a hPRL-G129R [82] 
(Figure 6).  
 
We envisaged that prolactin secretion and/or PRLR 
expression might be affected by pharmacological 
blockade of FASN activity. The achievement of 
higher levels of autocrine prolactin secretion (and 
PRLR expression) obligatorily required the presence 
of the PR-B isoform. Thus, PR-A+ T47-YA cells and, 
more notably, PR-null T47D-Y cells, secreted less 
prolactin and downregulated PRLR expression in 
comparison with PR-A+/PR-B+ T47Dco cells. With 
the sole exception of sexual hormone (estradiol and 
androgen)-induced transcriptional up-regulation of 
autocrine prolactin in rat trigeminal neurons, pituitary 
lactotrophs, and rat prostate [121, 122], the 
pathway(s) that regulate the synthesis and secretion of 
autocrine prolactin in breast cancer cells are largely 
unknown. The PTEN/PI3K-AKT pathway – one of the 
most commonly activated metabolic drivers of cancer 
– is an upstream regulator of autocrine prolactin 
production in the normal mammary gland; moreover, 
autocrine prolactin production is a direct mechanism 
by which PI3K-AKT activation results in 
PRLR/JAK2/STAT5 pathway activation [123]. 
Importantly, whereas AKT-induced up-regulation of 
autocrine prolactin does not require intact 
PRLR/JAK/STAT5 signaling, the PRLR/JAK/STAT5 
pathway is required to mediate the effects of AKT on 
lipid synthesis in the normal mammary gland [123]. 
We found that the ability of the FASN inhibitor C75 
to reduce prolactin secretion in PR-A+/PR-B+ 
T47Dco parental cells was either exacerbated in  
PR-B+ T47D-YB cells or partially dampened in PR-
A+ T47-YA cells. Because AKT is rapidly repressed 
in response to C75-induced blockade of FASN 




Figure 6. A PR isoform-dependent cross-talk between prolactin and FASN in breast cancer: a working model. The convergence of 
prolactin/PRLR and PR signaling interactions on STAT5 [130, 131] might explain, at least in part, the PR-B-driven capacity of prolactin to activate 
FASN in luminal breast cancer cells (A). Similar inputs, likely involving yet-to-be explored phospho-modifications of PR isoforms, might underlie also 
the ability of FASN signaling to regulate autocrine prolactin secretion (B).   
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feedback regulation between FASN and autocrine 
prolactin expression via AKT-driven activation of the 
PRLR/JAK/STAT5 pathways in PR+ breast cancer 
cells. This positive feedback, however, is apparently 
fine-tuned by PR signaling in a PR isoform-specific 
manner, which might reflect, at least in part, the ability 
of PR-B to cause down-regulation of the PI3K/AKT 
signal via upregulation of PTEN [126]. In T47D-Y cells 
lacking PRs and exhibiting a more aggressive 
undifferentiated phenotype, the suppression of FASN 
signaling was accompanied by a partial recovery of 
prolactin secretory activation, up-regulation of PRLR 
expression, and down-regulation of EMT/cancer stem 
cell/pro-inflammatory markers such as IL-6. These 
findings, overall, suggest that the ability of FASN 
signaling to enable secretory activation of endocrine 
prolactin is a PR-dependent event that might dictate the 
level of luminal cell differentiation [38]. Further 
characterization of the FASN-centered relationship 
between PRs, prolactin/PRLR/JAK/STAT5, and PI3K/ 
AKT pathways will be required to determine whether 
therapeutic approaches directed at blocking the 
interaction between these pathways would be more 
beneficial to therapeutically manage prolactin and/or 
FASN signaling in breast cancer cells. Nonetheless, it is 
important to acknowledge that we employed the FASN 
inhibitor C75 in the form of a racemic mixture of (-) 
and (+) enantiomers, which differ in their regulation of 
FASN and carnitine palmitoyltransferase-I (CPT-1) 
[127–129]. An evaluation of clinical-grade FASN 
inhibitors devoid of CPT-I inhibitory activity should 
definitely clarify the mechanistic role of FASN as a 
therapeutic target for differentiation therapy in certain 
subsets of ER+/PR- breast carcinomas [38] 
 
In summary, our data reveal an unforeseen PR-B 
isoform-specific regulatory action on the cross-talk 
between prolactin and FASN signaling in luminal breast 
cancer cells. Our data suggest that the lipogenic FASN 
might be incorporated into the group of metabolic 
markers specifically enriched by PR-B (but not with 
those related to the malignant metabolism of cancer 
stem cells enriched by PR-A) in luminal A-like PR+ 
breast cancer cells [130–133], likely promoting 
survival, proliferation, and differentiation. In ER-
positive/PR-negative luminal B-like breast cancer cells, 
however, FASN signaling might be co-opted as a 
negative regulator of the epithelial cell phenotype and, 
accordingly, its blockade might promote the restoration 
and activation of prolactin/PRLR-driven differentiation 
programs. Nonetheless, because the PR isoform ratio is 
a proxy for the molecular signature and endocrine 
therapy responsiveness of PR+ breast cancer cells, our 
findings might illuminate new PR-B/FASN-centered 
predictive and therapeutic modalities in luminal breast 
cancer intrinsic subtypes. 




Anti-PR (clone hPRa2 + hPRAa3, Ab-8) and anti-PRLR 
(Ab-1) mouse monoclonal antibodies were purchased from 
Lab Vision Corporation (Fremont, CA). Anti-FASN 
mouse monoclonal antibody (clone 23) was purchased 
from BD PharMingen Laboratories (San Diego, CA). 
Anti-β-actin goat polyclonal antibody was purchased from 
Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). 
 
Profiling of breast cancer datasets 
 
We interrogated the publicly available Molecular 
Taxonomy of Breast Cancer International Consortium 
(METABRIC) breast cancer dataset from the UK and 
Canada, in which mRNA expression was measured 
using the Illumina HT-12v13 platform and copy number 
alterations with the Affymetrix SNP 6.0 array. Gene-
level expression files from METABRIC were 
downloaded from the cBioportal for Cancer Genomics 
(https://www.cbioportal.org/). We used the 3-gene and 
PAM50 breast cancer intrinsic subtypes provided in the 




Human T47Dco breast cancer cells co-expressing PR-A 
and PR-B, T47DY cells lacking PRs, T47D-YA cells 
expressing only PR-A, and T47D-YB cells expressing 
only PR-B were generously provided by Dr. K. B. 
Horwitz (University of Colorado). MCF-7/neo and 
MCF-7/Her2-18 breast cancer cells stably 
overexpressing the HER2 oncogene were kindly 
provided by Dr Mien-Chie Hung (University of Texas 
M.D. Anderson Cancer Center). Cells were grown in 
Improved Minimal Essential Medium (IMEM) with 5% 
fetal bovine serum and 2 mmol/L L-glutamine. Before 
starting any experimental treatment, cells were cultured 
and washed extensively with phenol red-free IMEM 
supplemented with 5% dextrin-coated charcoal-treated 
bovine serum (CCS) for 3 days to ensure complete 




Cells were washed twice with phosphate buffered saline 
(PBS) and lysed in a lysis buffer (20 mM Tris [pH 7.5], 
150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton X-
100, 2.5 mM sodium pyrophosphate, 1 mM β-
glycerolphosphate, 1 mM Na3VO4, 1 μg/ml leupeptin, 1 
mM phenylmethylsulfonylfluoride) for 30 min on ice. 
Lysates were cleared by centrifugation in an Eppendorf 
tube (15 min at 14 000 rpm, 4° C). Protein content was 
determined against a standardized control using the Pierce 
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Protein Assay Kit (Rockford, IL). Equal amounts of 
protein (50 μg in the case of PR and PRLR, 10 μg in the 
case of FASN) were resuspended in 5× Laemmli sample 
buffer for 10 min at 70° C, subjected to electrophoresis on 
either 10% SDS-PAGE gels (Novex, San Diego, CA) in 
the case of PRs and PRLR or 3–8% NuPAGE Tris-Acetate 
gels (Novex) in the case of FASN, and transferred to 
nitrocellulose membranes. Nonspecific binding was 
minimized by blocking for 1 h at room temperature with 
TBS-T (25 mM Tris-HCl, 150 mM NaCl [pH 7.5], and 
0.05% Tween 20) containing 5% (w/v) nonfat dry milk. 
Membranes were then washed in TBS-T and incubated 
for 2 h at room temperature with specific primary 
antibodies in TBS-T/5% (w/v) nonfat dry milk. 
Membranes were washed again in TBS-T, horseradish 
peroxidase-conjugated secondary antibodies (Jackson 
Immunoresearch Labs, West Grove, PA) in TBS-T were 
added for 1 h, and immunoreactive bands were detected 
by enhanced chemiluminescence reagent (Pierce). Blots 
were re-probed with an antibody for β-actin to control 
for protein loading and transfer. Figures show 
representative immunoblot analyses. Similar results 
were obtained in 3 independent experiments.  
 
FASN gene promoter activity 
 
To analyze FASN gene promoter activity, estradiol-
depleted cells seeded in 24-well plates (~ 5 × 10
4
 
cells/well) were transfected (FuGENE 6; Roche 
Biochemicals, Indianapolis, IN) in low-CCS (0.5% 
CCS) IMEM with 300 ng/well of the pGL3-luciferase 
(Promega, Madison, WI) construct containing a 
luciferase reporter gene driven by either an intact 178-
bp FAS promoter fragment harboring a well-
characterized SREBP-binding site flanked by auxiliary 
NF-Y and Sp-1 sites, or with a similar construct in 
which the SREBP-binding site was deleted. Cells were 
contransfected with 30 ng/well of the internal control 
plasmid pRL-CMV, which was used to correct for 
transfection efficiency. After 18 h, the transfected cells 
were washed and then incubated in 0.5% CCS for 
approximately 24 h. Luciferase activity was detected 
using the Luciferase Assay System (Promega) with a 
TD-20/20 luminometer (Turner Designs, Sunnyvale, 
CA). The magnitude of activation in FASN promoter-
luciferase-transfected cells was determined after 
normalization to the luciferase activity in cells co-
transfected with equivalent amounts of the empty 
pGL3-luciferase vector (∅-Luc) and the internal control 
plasmid pRL-CMV, which was taken as 1.0-fold. This 
control value was used to calculate the relative (fold) 
change in transcriptional activities of FASN promoter-
luciferase-transfected cells in response to treatments 
after normalization to pRL-CMV activity, and the data 
are shown as the means (columns) ± S.D. (bars) from 
three separate experiments (performed in triplicate). 
Prolactin and IL-6 secretion 
 
T47Dco, T47D-Y, T47-YA and T47-YB cells were 
depleted of estradiol by treatment with 5% CCS for 3 days, 
washed twice with pre-warmed PBS and cultured in 
serum-free medium overnight. Cells were then cultured in 
0.5% CCS for up to 48 h in the absence or presence of 
graded concentrations of the synthetic FASN inhibitor 
C75. After this, the conditioned medium was collected, 
centrifugated at 1,000 × g for 10 min at 4° C to remove 
debris, and stored at -80° C until analysis. The amount of 
prolactin in conditioned media was determined with an 
enzyme amplified sensitivity immunoassay (Catalog# 
KAQ1441; Biosource International, Hopkinton, MA). The 
amount of IL-6 conditioned media was determined with 
the Human IL-6 Quantikine ELISA Kit (catalog #D6050; 
R&D Systems, Minneapolis, MN). Data shown are means 
(columns) ± S.D. (bars) from three independent 




For all experiments, at least three independent experiments 
were performed with n≥3 replicate samples per 
experiment. No statistical method was used to 
predetermine sample size. Investigators were not blinded 
to data allocation and experiments were not randomized. 
Data are presented as mean ± S.D. Comparisons of means 
of ≥3 groups were performed by one-way analysis of 
variance (ANOVA) and Dunnett’s t-test for multiple 
comparisons using XLSTAT 2010 (Addinsoft, Long 
Island, NY). In all studies, P-values <0.05 and <0.005 
were considered to be statistically significant (denoted as * 
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Supplementary Figure 1. Effects of FASN inhibition on expression of progesterone receptor isoforms. Immunoblotting of PR-A 
and PR-B proteins in T47Dco, T47D-Y, T47D-YA and T47D-YB breast cancer cell lines cultured in the absence or presence of graded 
concentrations of C75. β-actin was used to control for protein loading and transfer.  
